Metformax

Metformin Hydrochloride, the active ingredient in Metformax, is a biguanide presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus and related glucose‑handling disorders. GNH USA supplies Metformax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformax is an oral biguanide used to improve glycaemic control in disorders of glucose metabolism.

Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels to achieve target HbA1c. Prediabetes (impaired glucose tolerance): delays progression to overt diabetes by improving insulin sensitivity. Polycystic ovary syndrome (off‑label): reduces insulin resistance and may help normalize menstrual cycles.

Metformax may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal discomfort) - Diarrhoea - Metallic taste in the mouth - Loss of appetite - Mild headache

Serious or Rare Side Effects: - Lactic acidosis (rare but potentially fatal) - Severe hypoglycaemia when combined with insulin or sulfonylureas - Hepatic dysfunction - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Persistent vomiting leading to dehydration

Before initiating Metformax, consider patient‑specific factors and monitor for adverse events.

Renal function: avoid or adjust dose in patients with impaired renal clearance. Hepatic disease: use with caution; monitor liver enzymes. Cardiovascular status: assess for heart failure, as lactic acidosis risk may increase. Alcohol consumption: limit intake to reduce lactic acidosis risk. Pregnancy and lactation: evaluate risk‑benefit; generally avoid unless clearly needed. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Metformax can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Intravenous contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Certain antiretrovirals (e.g., didanosine): increase risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycaemia. - Diuretics (especially thiazides): may affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes.